title: Anti-Müllerian hormone and assessment of ovarian reserve after ovarian toxic treatment: a systematic narrative review.
abstract: Since serum anti-Müllerian hormone (AMH) levels enable quantitative evaluation of ovarian damage, we conducted a computer-based search, using key words, of all articles published in English through the PubMed database from inception until September 2013 to summarize available studies evaluating ovarian reserve after ovarian toxic interventions to discuss the usefulness of serum AMH levels. We found that most of the studies demonstrated a decline in serum AMH levels when compared to control or pretreatment levels, with levels dependent on the type of treatment modality. Measurement of serum AMH levels enables quantitative evaluation of ovarian damage caused by ovarian toxic interventions, such as chemotherapy and radiotherapy, instead of qualitative evaluation using menstrual condition or basal follicle-stimulating hormone levels. Serum AMH levels are becoming indispensable to assess the ovarian reserve of patients who desire preservation of ovarian function for fertility and endogenous sex steroid hormones.
authors.affiliation: Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Showa-ku, Nagoya, Japan Department of Maternal and Perinatal Medicine, Nagoya University Hospital, Showa-ku, Nagoya, Japan akiwase@med.nagoya-u.ac.jp.
authors.forename: Akira
authors.initials: A
authors.lastname: Iwase
authors.affiliation: Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Showa-ku, Nagoya, Japan.
authors.forename: Tomoko
authors.initials: T
authors.lastname: Nakamura
authors.affiliation: Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Showa-ku, Nagoya, Japan.
authors.forename: Tatsuo
authors.initials: T
authors.lastname: Nakahara
authors.affiliation: Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Showa-ku, Nagoya, Japan.
authors.forename: Maki
authors.initials: M
authors.lastname: Goto
authors.affiliation: Department of Obstetrics and Gynecology, Nagoya University Graduate School of Medicine, Showa-ku, Nagoya, Japan.
authors.forename: Fumitaka
authors.initials: F
authors.lastname: Kikkawa
mesh_terms: D054304:Anti-Mullerian Hormone / Q000097:blood*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D015415:Biomarkers / Q000097:blood; D015536:Down-Regulation; D005260:Female; D059247:Fertility Preservation; D006801:Humans; D007247:Infertility, Female / Q000097:blood / Q000139:chemically induced* / Q000503:physiopathology; D065851:Ovarian Reserve / Q000187:drug effects* / Q000528:radiation effects*; D010053:Ovary / Q000187:drug effects* / Q000378:metabolism / Q000473:pathology / Q000503:physiopathology; D011237:Predictive Value of Tests; D011832:Radiation Injuries / Q000097:blood / Q000209:etiology* / Q000503:physiopathology; D011878:Radiotherapy / Q000009:adverse effects; D012307:Risk Factors
chemical_list: D000970:Antineoplastic Agents; D015415:Biomarkers; D054304:Anti-Mullerian Hormone
keywords: anti-Müllerian hormone; chemotherapy; oncofertility; ovarian reserve